Senti Biosciences Holdings, Inc. (SNTI) shareholders
Close on Nov 17, 2026Market cap $3.02MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Celadon Partners SPV 24 Joint filing with Celadon Partners, LLC (54.60%), CPIF II-7 Limited (54.60%) | 25,748,890 | 54.60% | 13D (active) amendment | Apr 27, 2026 |
| CPIF II-7 Limited Joint filing with Celadon Partners SPV 24 (54.60%), Celadon Partners, LLC (54.60%) | 25,748,890 | 54.60% | 13D (active) amendment | Sep 3, 2026 |
| Celadon Partners, LLC Joint filing with Celadon Partners SPV 24 (45.00%) | 13,511,322 | 45.00% | 13D (active) amendment | Jan 19, 2026 |
| Gurumurthy Ramamurthy Joint filing with Bayer HealthCare LLC (19.99%), Bayer US Holding LLC (19.99%) and 1 more | 6,142,848 | 19.99% | 13D (active) | Mar 10, 2025 |
| Bayer US Holding LLC Joint filing with Bayer HealthCare LLC (17.82%), Sebastian Guth (17.82%) and 1 more | 6,142,848 | 17.82% | 13D (active) amendment | Mar 27, 2026 |
| Mohamad H. Makhzoumi Joint filing with New Enterprise Associates 15, L.P. (12.10%), NEA Partners 15, L.P. (12.10%) and 4 more | 3,775,615 | 12.10% | 13D (active) amendment | Mar 27, 2026 |
| NEA Partners 15, L.P. Joint filing with New Enterprise Associates 15, L.P. (14.50%), Nea 15 Gp, LLC (14.50%) and 4 more | 3,775,615 | 14.50% | 13D (active) amendment | Mar 6, 2025 |
| Daniel Mack Joint filing with Nantahala Capital Management, LLC (8.12%), Wilmot B. Harkey (8.12%) | 2,220,000 | 8.12% | 13G (passive) amendment | Mar 31, 2025 |
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 536,010 | 9.99% | 13G (passive) | Dec 31, 2024 |
| Wilmot B. Harkey Joint filing with Nantahala Capital Management, LLC (9.99%), Daniel Mack (9.99%) | 509,283 | 9.99% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SNTI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 3,775,615 | 12.12% | $4.15M | – | 0.26% |
| Nantahala Capital Management, LLC | 888,000 | 2.85% | $976.80K | – | 0.02% |
| Vanguard Capital Management LLC | 537,504 | 1.73% | $591.25K | – | 0.00% |
| Geode Capital Management, LLC | 187,065 | 0.60% | $205.78K | −19,978 | 0.00% |
| Citadel Advisors LLC | 107,100 | 0.34% | $117.81K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 91,193 | 0.29% | $100.31K | – | 0.00% |
| Jane Street Group, LLC | 52,530 | 0.17% | $57.78K | New | 0.00% |
| Menlo Ventures Management, L.P. | 35,737 | 0.11% | $39.31K | – | 0.01% |
| Northern Trust Corp | 32,154 | 0.10% | $35.37K | +15,376 | 0.00% |
| XTX Topco Ltd | 23,610 | 0.08% | $25.97K | +6,333 | 0.00% |
| Virtu Financial LLC | 22,795 | 0.07% | $25.00K | New | 0.00% |
| UBS Group AG | 14,432 | 0.05% | $15.88K | +5,795 | 0.00% |
| Tower Research Capital LLC (TRC) | 7,344 | 0.02% | $8.08K | New | 0.00% |
| Royal Bank of Canada | 4,015 | 0.01% | $4.00K | New | 0.00% |
| BlackRock, Inc. | 4,004 | 0.01% | $4.40K | −21,070 | 0.00% |
| Barclays PLC | 768 | 0.00% | $845 | New | 0.00% |
| SBI Securities Co., Ltd. | 334 | 0.00% | $367 | – | 0.00% |
| Morgan Stanley | 169 | 0.00% | $186 | +9 | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | 0.00% | $1 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 19 | 6M | 18.6% | 6 / 4 | 2 / 3 | 0M | 0M |
| Q1 2026 | 16 | 6M | 18.1% | 7 / 3 | 1 / 4 | 1M | 0M |
| Q4 2025 | 15 | 6M | 18.0% | 4 / 4 | 2 / 5 | 0M | 0M |
| Q3 2025 | 16 | 6M | 18.8% | 5 / 4 | 2 / 4 | 0M | 1M |
| Q2 2025 | 15 | 7M | 21.6% | 1 / 5 | 3 / 2 | 1M | 0M |
| Q1 2025 | 16 | 6M | 19.0% | 4 / 7 | 0 / 4 | 5M | 0M |
| Q4 2024 | 16 | 1M | 3.0% | 4 / 2 | 6 / 2 | 0M | 0M |
| Q3 2024 | 14 | 1M | 3.4% | 5 / 6 | 2 / 10 | 0M | 0M |
| Q2 2024 | 20 | 1M | 3.3% | 3 / 3 | 4 / 10 | 0M | 0M |
| Q1 2024 | 27 | 1M | 3.5% | 7 / 3 | 3 / 5 | 0M | 0M |
| Q4 2023 | 25 | 1M | 3.7% | 5 / 5 | 1 / 6 | 0M | 0M |
| Q3 2023 | 26 | 1M | 3.9% | 3 / 5 | 5 / 5 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
9 funds held SNTI in Q1 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SNTI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 368,878 | 1.18% | $405.77K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 168,626 | 0.54% | $185.49K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 95,866 | 0.31% | $91.23K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 24,798 | 0.08% | $23.60K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 19,991 | 0.06% | $19.02K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 18,801 | 0.06% | $17.89K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -100 | -0.00% | -$110 | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Timothy K. Lu | CEO, Director | 587,949 | 1.89% | Oct 23, 2026 |
| Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | 87,890 | 0.28% | Oct 23, 2026 |
| John Harry Cross III | Chief Financial Officer | – | – | Mar 11, 2025 |
| Bryan Daniel Baum | Director | – | – | Jul 21, 2025 |
| Donald F. Tang | Director | 10,368 | 0.03% | Jun 27, 2025 |
| Edward T. Mathers | Director | – | – | Jun 27, 2025 |
| James J. Collins | Director | 176,130 | 0.57% | Jun 27, 2025 |
| Fran Schulz | Director | – | – | Jun 27, 2025 |
| Brenda Cooperstone | Director | – | – | Jun 27, 2025 |
| Feng Hsiung | Director | – | – | Jun 27, 2025 |
| Partners SPV 24 Celadon | 10% owner | 9,777,000 | 31.39% | Mar 14, 2025 |
| Mohamad Makhzoumi | 10% owner | – | – | Mar 12, 2025 |
| Forest Baskett | 10% owner | – | – | Mar 12, 2025 |
| World Investments B.V. Bayer | 10% owner | – | – | Mar 12, 2025 |
| Anthony A. Florence Jr. | 10% owner | 3,775,615 | 12.12% | Mar 12, 2025 |
| Scott D. Sandell | 10% owner | 442,615 | 1.42% | Mar 12, 2025 |
| US Holding LP Bayer | 10% owner | 2,809,848 | 9.02% | Mar 12, 2025 |
| Healthcare Llc Bayer | 10% owner | – | – | Mar 12, 2025 |
| New Enterprise Associates 15, L.P. | 10% owner | – | – | Mar 12, 2025 |
| Nea 15 Gp, Llc | 10% owner | 4,426,151 | 14.21% | Mar 12, 2025 |
| NEA Partners 15, L.P. | 10% owner | – | – | Mar 12, 2025 |
| Aktiengesellschaft Bayer | 10% owner | – | – | Mar 12, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kanya Rajangam Pres. & Chief Med. & Dev. Off. | Oct 21, 2026 | Tax withholding | −19,953 | – | – | 54,890 |
| Timothy K. Lu CEO, Director | Oct 21, 2026 | Tax withholding | −157,312 | – | – | 482,271 |
| Kanya Rajangam Pres. & Chief Med. & Dev. Off. | Mar 9, 2026 | Tax withholding | −10,757 | – | – | 74,843 |
| Timothy K. Lu CEO, Director | Mar 9, 2026 | Tax withholding | −80,666 | – | – | 639,583 |
| Kanya Rajangam Pres. & Chief Med. & Dev. Off. | Feb 2, 2026 | Tax withholding | −1,384 | – | – | 85,600 |
| Timothy K. Lu CEO, Director | Feb 2, 2026 | Tax withholding | −4,191 | – | – | 720,249 |
| Partners SPV 24 Celadon 10% owner | Mar 10, 2025 | Conversion | +9,777,000 | – | – | 9,777,000 |
| US Holding LP Bayer 10% owner | Mar 10, 2025 | Conversion | +2,222,000 | – | – | 2,809,848 |
| Anthony A. Florence Jr. 10% owner | Mar 10, 2025 | Conversion | +3,333,000 | – | – | 3,775,615 |
| Kanya Rajangam Pres. & Chief Med. & Dev. Off. | Mar 10, 2025 | Conversion | +33,000 | $2.25 | $74.25K | 33,000 |
| Timothy K. Lu CEO and Interim PFO and PAO, Director | Mar 7, 2025 | Award | +642,358 | – | – | 724,440 |
| Kanya Rajangam Pres. & Chief Med. & Dev. Off. | Mar 7, 2025 | Award | +78,363 | – | – | 86,984 |
| Timothy K. Lu CEO, Director | Feb 6, 2025 | Sale | −545 | $4.36 | $2.38K | 82,082 |
| Kanya Rajangam Pres. & Chief Med. & Dev. Off. | Feb 6, 2025 | Sale | −182 | $4.37 | $795 | 8,621 |
| Timothy K. Lu CEO, Director | Feb 4, 2025 | Sale | −3,922 | $4.07 | $15.96K | 82,627 |
| Kanya Rajangam Pres. & Chief Med. & Dev. Off. | Feb 4, 2025 | Sale | −1,297 | $4.07 | $5.28K | 8,803 |
| Kanya Rajangam Chief Medical & Devt. Officer | Feb 1, 2024 | Award | +101,000 | – | – | 101,000 |
| Deborah Knobelman Chief Financial Officer | Feb 1, 2024 | Award | +101,000 | – | – | 131,000 |
| Timothy K. Lu CEO and President, Director | Feb 1, 2024 | Award | +306,000 | – | – | 865,496 |
| Deborah Knobelman Chief Financial Officer | Oct 3, 2022 | Award | +30,000 | – | – | 30,000 |
| Sponsor LLC Dynamics Director, 10% owner | Jun 8, 2022 | Other | −6,465,500 | – | – | 0 |
| Sponsor LLC Dynamics Director, 10% owner | Jun 8, 2022 | Option exercise | +5,750,000 | – | – | 6,465,500 |
| David R. Epstein Director | Jun 8, 2022 | Award | +112,519 | – | – | 123,252 |
| Omid Farokhzad Director | Jun 8, 2022 | Award | +250,000 | $10.00 | $2.50M | 250,000 |
| Omid Farokhzad Director | Jun 8, 2022 | Other | −4,518,097 | – | – | 1,947,403 |
| Omid Farokhzad Director | Jun 8, 2022 | Option exercise | +5,750,000 | – | – | 6,465,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Senti Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 24,629 shares on Aug 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Omid Farokhzad Former Affiliate | Dec 2, 2024 | 83,277 | $179.88K | Dec 2, 2024 | Founder shares |
See a number that looks wrong?